Childhood leukemia is the stage of a breakthrough era of drug discovery and development as scientists employ computational tools to derive deeper insights regarding drug response and resistance, mechanisms of action, and more from single cell and bulk RNA-seq data, and inform decisions on new therapeutic approaches.
Aiosyn, a pioneering pathology software company specializing in AI-powered solutions for kidney disease and breast cancer, has integrated its glomerular quantification algorithm with Sectra’s diagnostic application for pathology. As the first solution for kidney biopsy analysis featured on Sectra Amplifier Marketplace, NephroPath GlomeruCount* allows kidney pathology laboratories to boost the efficiency of tissue evaluations.
Perihilar cholangiocarcinoma (PHCC), also known as Klatskin tumors, represents one of the most challenging malignancies in oncology. With an incidence rate of 1-2 cases per 100,000 individuals in the Western world, this rare cancer is characterized by late diagnosis and poor long-term survival rates, even with curative surgical treatment. Artificial intelligence (AI) has emerged as a promising tool in oncology, particularly through AI-based digital histopathology, offering the potential to improve prognostic predictions in various cancers, including PHCC. However, while AI offers significant advancements, its role in PHCC remains a step forward, but not yet the leap required for clinical impact.
10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced the launch of Chromium Xo, a new addition to its fleet of Chromium single cell instruments. Designed to meet the needs of researchers who desire high-quality data on limited budgets, Chromium Xo offers an affordable entry point into routine, high-performance single cell analysis.
Fimlab Laboratories, Finland’s largest provider of laboratory services, research, and training, is taking the next step on its digital pathology journey with Proscia®, a global leader in AI-enabled pathology solutions for precision medicine. The company will use Proscia’s software platform to help its pathologists generate more precise results with artificial intelligence (AI).
PathAI, a global leader in artificial intelligence (AI) and digital pathology solutions, today announced the launch of MET Predict† on the AISightⓇ† Image management system (IMS). MET Predict is an AI-powered algorithm designed to help pathologists identify non-small cell lung cancer (NSCLC) tumors that may be more likely to have MET exon 14 skipping (METex14) or MET amplification, directly from an H&E whole slide image.
Proscia®, a global leader in AI-enabled pathology solutions for precision medicine, and Smart Reporting, a leading provider of medical documentation software, have partnered to help pathologists inform treatment decisions. The companies will deliver a unified experience around a product integration that enables pathologists to efficiently make and comprehensively report on precise diagnoses, all within a single user interface.
Click the button below to register for your DDx virtual access tickets. All-inclusive tickets to this year's highly anticipated Digital Diagnostic Summit (DDx) have officially sold out. If you missed your chance to secure one, there’s good news: the DDx Summit is offering Virtual Access tickets, meaning you can still participate in the event remotely. With this [...]
Oracle and Imagene, a pioneer in AI-based precision oncology, today announced CanvOI, a state-of-the-art pan-cancer foundation model designed to facilitate innovative research and development in the digital pathology and oncology space. Running on Oracle Cloud Infrastructure (OCI), CanvOI captures the complex features and patterns within biopsy images, providing valuable oncology intelligence that could improve the way cancer is diagnosed and treated around the world.
The seamless integration is facilitated through Roche's navify® Digital Pathology enterprise software, an application for the pathologist's workflow, which now incorporates a diverse range of AI-driven algorithms, creating easy access to third-party innovation. These AI tools are designed to enhance pathology insights, helping benefit cancer patients through precision medicine and enabling targeted treatments.
